When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
SBBP - Strongbridge Appears An Incredible Value After Releasing Recorlev's Phase 3 Data
Strongbridge Biopharma plc
Our analysis concludes Strongbridge Biopharma PLC (SBBP) is materially undervalued now that SBBP has reported positive Phase 3 topline date for Recorlev. This is primarily because Recorlev should (soon if not now) be worth at least 2 (but probably 3) times its estimated peak annual sales of $250MM to $350MM per year as guided by SBBP management. SBBP's market cap of $150MM at $2.70/share is only a fraction of Recorlev's value at 2 to 3 times estimated peak annual sales of $500MM to $1.05Billion. It is now up to SBBP management to, one